Integrated DNA Technologies (IDT), a genomics solutions provider, is developing a multiplex RT-qPCR test that can detect and distinguish between SARS-CoV-2, influenza A and influenza B from a single patient sample, according to a press release from the company.
The new PrimeTime SARS-CoV-2/Flu Test is being submitted by IDT for emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA), IDT said.
The test is the first in vitro diagnostic product being developed by IDT, which manufactures custom nucleic acids for life sciences researchers. The PrimeTime SARS-CoV-2/Flu Test will be able to be utilized as an “open system solution” validated on several different instrument platforms, enabling more widespread use, the company said.
